MacroGenics, Inc. (NASDAQ:MGNX) Stock Holdings Lessened by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lessened its holdings in shares of MacroGenics, Inc. (NASDAQ:MGNX) by 3.5% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 492,765 shares of the biopharmaceutical company’s stock after selling 17,740 shares during the period. Charles Schwab Investment Management Inc.’s holdings in MacroGenics were worth $1,621,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. raised its position in shares of MacroGenics by 64.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,064 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 4,707 shares during the period. DRW Securities LLC bought a new position in shares of MacroGenics during the 2nd quarter valued at about $56,000. K2 Principal Fund L.P. bought a new position in shares of MacroGenics in the second quarter valued at $63,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in MacroGenics by 300.6% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,072 shares of the biopharmaceutical company’s stock worth $68,000 after buying an additional 12,060 shares during the period. Finally, SG Americas Securities LLC acquired a new position in MacroGenics in the 3rd quarter worth approximately $55,000. Institutional investors and hedge funds own 96.89% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on MGNX shares. JMP Securities downgraded shares of MacroGenics from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 7th. HC Wainwright reissued a “neutral” rating and issued a $4.00 target price on shares of MacroGenics in a research note on Wednesday, November 6th. StockNews.com upgraded MacroGenics from a “sell” rating to a “buy” rating in a report on Sunday, November 10th. Finally, Evercore ISI raised shares of MacroGenics to a “strong-buy” rating in a research note on Monday, September 16th. Eight analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $7.63.

MacroGenics Trading Up 0.9 %

NASDAQ MGNX opened at $3.23 on Tuesday. The firm has a market capitalization of $202.72 million, a P/E ratio of -2.04 and a beta of 2.04. MacroGenics, Inc. has a 1 year low of $2.95 and a 1 year high of $21.88. The firm’s fifty day moving average price is $3.68 and its two-hundred day moving average price is $3.89.

About MacroGenics

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.